Report Type : Therapy Reports

Report Category : Oncology

Report Subcategory : Hormone Refractory or Castration Resistant, Androgen-Independent Prostate Cancer

Price : 2999.00

Date : November 2024

Hormone Refractory or Castration Resistant, Androgen-Independent Prostate Cancer : Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Hormone Refractory or Castration Resistant, Androgen-Independent Prostate Cancer:
Hormone-refractory prostate cancer (HRPC) and androgen-independent prostate cancer (AIPC) are terms that are often used interchangeably to describe prostate cancer that continues to grow after hormone therapy:

• Explanation
  Prostate cancer is considered hormone-refractory or androgen-independent when it continues to grow despite initial hormone therapy, such as surgical castration or chemical castration. The preferred term for this condition is castration-resistant prostate cancer (CRPC).

• Symptoms
  The first sign of hormone-refractory or androgen-independent prostate cancer is usually a rising PSA level.

• Treatment
  Standard treatment for hormone-refractory or androgen-independent prostate cancer includes continued castration with LHRH agonists in combination with docetaxel-containing chemotherapy. Other treatment options include hormones, chemotherapeutic agents, radioisotopes or radiotherapy, and bisphosphonates.

• Prognosis
  The median survival for patients with hormone-refractory or androgen-independent prostate cancer is between 10 and 20 months.

Top 50 Key Players:

1. Johnson & Johnson

2. F. Hoffmann-La Roche Ltd

3. Pfizer Inc

4. Bayer AG

5. Novartis AG

6. Merck & Co Inc

7. Sanofi

8. Abbott Laboratories

9. Bristol-Myers Squibb Co

10. AstraZeneca Plc

11. Amgen Inc

12. Gilead Sciences Inc

13. Boehringer Ingelheim International GmbH

14. Fujifilm Holdings Corp

15. Otsuka Holdings Co Ltd

16. Astellas Pharma Inc

17. Regeneron Pharmaceuticals Inc

18. Eisai Co Ltd

19. A. Menarini Industrie Farmaceutiche Riunite Srl

20. CareGroup Inc

21. Orion Corp

22. Hanmi Science Co Ltd

23. SRI International

24. Corcept Therapeutics Inc

25. Halozyme Therapeutics Inc

26. Nektar Therapeutics

27. Athenex Inc

28. Panacea Biotec Ltd

29. Arvinas Inc

30. Salarius Pharmaceuticals Inc

31. CTI BioPharma Corp

32. AnGes Inc

33. TBG Diagnostics Ltd

34. MEI Pharma Inc

35. Merrion Pharmaceuticals Plc

36. e-Therapeutics Plc

37. Cantex Pharmaceuticals Inc

38. Oncologie Inc

39. Bio-Cancer Treatment International Ltd

40. Celtek Bioscience LLC

41. Peking University

42. Metromedia Bio-Science LLC

43. University of Tokyo

44. Hebei General Hospital

45. NantWorks LLC

46. Mediolanum farmaceutici SpA

47. Fujifilm Holdings Corporation

48. Jyant Technologies Inc

49. DexTech Medical AB

50. Velacor Therapeutics Pty Ltd